Does Myrbetriq Affect Blood Pressure?
Myrbetriq (mirabegron) can raise blood pressure, particularly systolic blood pressure, in some patients. Clinical trials showed average increases of 3/4 mmHg in healthy adults and up to 8/9 mmHg in overactive bladder patients over 12 weeks, with effects persisting or growing over 12 months.[1][2] The FDA label warns of hypertension risk and recommends monitoring blood pressure before and during treatment, especially in those with uncontrolled hypertension.[1]
Can Patients with High Blood Pressure Take It?
No, Myrbetriq is not recommended for patients with severe uncontrolled hypertension (systolic >180 mmHg or diastolic >110 mmHg). Use caution in mild to moderate hypertension; monitor closely and consider discontinuing if blood pressure rises significantly. It's contraindicated in those with end-stage renal disease on dialysis due to related risks.[1]
What Do Real-World Studies Show?
Post-marketing data and meta-analyses confirm small but consistent blood pressure elevations. A 2020 review of 29 trials found systolic increases of 0.5-1.5 mmHg overall, higher (up to 4 mmHg) in uncontrolled hypertensives. Serious cardiovascular events were rare but linked to dose (25 mg vs 50 mg).[3] No direct mortality risk, but avoid in patients with unstable heart conditions.
How Does It Compare to Other OAB Drugs?
Unlike anticholinergics (e.g., oxybutynin), which have minimal blood pressure impact, Myrbetriq's beta-3 agonist action can stimulate beta-1 receptors at higher doses, raising heart rate and pressure. Vesicare (solifenacin) or Gemtesa (vibegron) may be safer alternatives for hypertensives, with Gemtesa showing neutral blood pressure effects in trials.[1][4]
What Precautions Should Hypertensive Patients Follow?